Compare Mesoblast Limited (MESO) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while YieldMax TSLA Option Income Strategy ETF trades at $25.75. The key difference: Mesoblast Limited is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MESO | TSLY | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $20.96 | $48.25 |
52-Week Low | $12.88 | $25.07 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TSLY trades at $25.07, down 2.57% over the past day, with a bearish technical outlook from moving averages and oscillators. The ETF maintains a high distribution yield, with weekly dividends averaging around $0.30 per share, though recent news highlights concerns about capped upside relative to Tesla's performance. Key support sits near $25, while resistance is at $26.
The outlook for TSLY is cautious due to its option income strategy limiting capital appreciation. Risks include volatility from Tesla's stock movements and potential erosion of principal from return of capital distributions. Investors seeking high yield may find value, but must weigh the trade-off between income and growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
